Recoflavone (DA-6034) is a synthetic derivative of eupatillen (flavone derivative). It has antioxidant properties, and anti-inflammatory effects in inflammatory bowel disease (IBD). Although the exact mechanism is still unknown, recoflavone may decrease intestinal permeability in an indomethacin-induced intestinal injury model via the extracellular signal-regulated kinase pathway. In a phase I clinical trial, recoflavone was well tolerated and minimally absorbed in healthy volunteers. In other (phase II and III) clinical trials, the drug has been evaluated for use in treatment of gastritis (phase III), dry eyes, and Crohn’s disease (discontinued).